Skip to content

Study · Not a test of the peptide alone · 2017

3 results

Targeted delivery of thymosin beta 4 to the injured myocardium using CREKA-conjugated nanoparticles.

Huang Z, Song Y, Pang Z, Zhang B, Yang H, Shi H, Chen J, Gong H, Qian J, Ge J

International journal of nanomedicine12 Apr 2017Cited by 33 (Europe PMC)

PMID28442910 (opens in a new tab)PMCIDPMC5396927 (opens in a new tab)DOI10.2147/ijn.s131949 (opens in a new tab)PepBankPUB-28442910
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 01AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Pharmacokinetics

    In mice with myocardial ischemia-reperfusion injury, CNP-Tβ4 targeted fibrin more strongly than NP-Tβ4 and accumulated mainly in the infarcted area.

    In plain wordsIn mice with heart injury, the targeted Tβ4 nanoparticles gathered in the damaged area more than the untargeted ones.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseFibrin targeting and accumulation in infarcted area
    Study

    mousen: not reported in source

    acute myocardial ischemia-reperfusion injury
    Comparator
    NP-Tβ4
    Outcome group
    Pharmacokinetics · Cardiovascular

    Source sentences

    Summary
    CNP-Tβ4 revealed a stronger fibrin-targeting ability than the NP-Tβ4 group and accumulated mainly in the infarcted area and colocalized with fibrin.
    1 context sentence
    Summary · context
    Based on the validation of fibrin expression in the early stage of ischemia injury, CNP-Tβ4 was intravenously administered to mice with acute myocardial ischemia-reperfusion injury.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 02AnimalNot a test of Thymosin beta-4 (human) aloneAnimal study (in vivo)Efficacy outcome

    In mice with myocardial ischemia-reperfusion injury, treatment with CNP-Tβ4 gave a better therapeutic effect; the abstract names no comparator or outcome.

    In plain wordsIn mice with heart injury, treatment with the targeted Tβ4 nanoparticles gave a better effect. The abstract does not say compared with what.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseTherapeutic effect of CNP-Tβ4
    Study

    mousen: not reported in source

    acute myocardial ischemia-reperfusion injury
    Outcome group
    Heart function · Cardiovascular

    Source sentences

    Summary
    Subsequently, treatment with CNP-Tβ4 resulted in a better therapeutic effect.
    1 context sentence
    Summary · context
    Based on the validation of fibrin expression in the early stage of ischemia injury, CNP-Tβ4 was intravenously administered to mice with acute myocardial ischemia-reperfusion injury.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  3. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Activity measurement

    In an in vitro test, CREKA-conjugated Tβ4 nanoparticles bound fibrin clots more than nanoparticles without CREKA.

    In plain wordsIn lab tests, the targeted Tβ4 nanoparticles stuck to blood clots more than the untargeted ones.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    IncreaseBinding of CNP-Tβ4 to fibrin clots
    Study

    n: not reported in source

    fibrin clots
    Comparator
    NP-Tβ4
    Outcome group
    Receptor activity and mechanism · Cardiovascular

    Source sentences

    Summary
    In vitro binding test revealed that CNP-Tβ4 had a significant binding ability to the surface of fibrin clots when compared to the control clots (NP-Tβ4).

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.